In a pilot study, Privè et al. prospectively assessed 10 BCR participants after local therapy, considered with low-tumor burden at [68Ga]Ga-PSMA-11 PET/ceCT (≤ 10 positive lesions). The gene discussed is BCR; the disease is neoplasm.